Foundayo for Weight Loss
Eli Lilly's daily weight loss pill, FDA approved April 2026. Unlike the semaglutide pills, it does not require an empty stomach, a 30-minute wait, or a specific time of day.
By GlobalGLP1 • FDA labels and makers’ information checked August 2026 • Updated October 2026 • Not a medical review
Jump to a section
Overview
Foundayo is a once-daily pill from Eli Lilly that was FDA approved in April 2026 for chronic weight management. It is a small-molecule GLP-1 tablet. Its label says to take it with or without food, and Lilly says it can be taken at any time of day. The active ingredient is orforglipron. In the ATTAIN-1 Phase 3 trial, people on the highest FDA-approved dose lost an average of 12.4% of their body weight over 72 weeks, estimated assuming everyone stayed on treatment (11.1% counting everyone who started). Its trial average was lower than those reported in the separate trials of injectable Wegovy and Zepbound, which have not been compared with it directly, but for people who cannot tolerate needles, travel often, or have run into injection supply shortages, the pill format is a real change. Foundayo is approved for adults with obesity (BMI 30 or higher) or with overweight (BMI 27+) plus a weight-related health condition like high blood pressure, type 2 diabetes, or sleep apnea.
How Foundayo Works
Foundayo is the brand name for orforglipron. It works by activating the GLP-1 receptor, the same hunger pathway that Wegovy and Ozempic target with injections. The difference is that Foundayo is a small-molecule pill. Its label says to take it once a day with or without food, and Lilly says it can be taken at any time of day without food or water restrictions.
FDA Approval
Foundayo
Chronic weight management in adults
0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg once-daily tablets (escalating dose; 17.2 mg is the highest dose)
How You Take It
Reaching the highest dose takes at least about five months (at least 30 days on each of five steps), and not everyone needs to go that high. Picking a consistent time each day helps you remember. If you miss a dose, take it as soon as you can, and do not take two doses in one day. If you miss 7 or more days in a row, ask your prescriber before you restart: the label says to restart at a lower dose to lower the risk of stomach side effects. The label says taking Foundayo together with another GLP-1 medicine is not recommended.
How Much Weight You Can Lose
In the ATTAIN-1 Phase 3 trial, people on the highest dose, 17.2 mg, lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo, estimated assuming everyone stayed on treatment. Counting everyone who started, the FDA label reports 11.1% at 17.2 mg, 8.3% at 9 mg and 7.4% at 5.5 mg, the three doses the trial tested, against 2.1% with placebo. For a 200-pound person on the highest dose, 12.4% is roughly 25 pounds.
Side Effects
Common Side Effects
- Nausea (35% at the 17.2 mg dose vs 10% on placebo in the two main Foundayo trials)
- Constipation (24% at 17.2 mg and 27% at 9 mg, vs 9%)
- Diarrhea (25% vs 11%)
- Vomiting (24% vs 4%)
- Indigestion (13% at 17.2 mg and 16% at 9 mg, vs 4%)
- Abdominal pain (14% vs 7%)
- Headache (9% vs 7%)
- Tiredness (9% vs 4%)
- Bloating (8% at 17.2 mg and 9% at 9 mg, vs 3%)
- Belching (8% vs 1%)
- Heartburn or reflux (7% vs 2%)
- Gas (6% vs 2%)
- Hair loss (5% vs 2%; 7% of women vs 0.9% of men)
Serious Side Effects
- Pancreatitis (inflamed pancreas): stop Foundayo and contact your provider if you have severe stomach pain that will not go away, sometimes spreading to your back
- Gallbladder disease
- Severe stomach and intestinal side effects (about 3% vs 1% on placebo); the label says Foundayo is not recommended for people with severe gastroparesis (very slow stomach emptying)
- Thyroid C-cell tumors (boxed warning; other GLP-1 drugs caused these tumors in rats and mice; orforglipron did not, but it does not act in those animals, and whether these tumors matter for people is not known)
- Acute kidney injury (linked to dehydration from severe vomiting or diarrhea)
- Low blood sugar. In the trial in people with type 2 diabetes, 2% on Foundayo had a blood sugar reading below 54 mg/dL, against 0.2% on placebo, and 7% of those also taking a sulfonylurea had low blood sugar. Taking it with insulin also raises the risk. In the trial in people without diabetes, low blood sugar was not systematically tracked, but 0.6% on Foundayo had a reading below 54 mg/dL, against none on placebo.
- Allergic reactions
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Temporary worsening of diabetic eye disease, linked to fast improvement in blood sugar, in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Other Reported Side Effects
- Faster heart rate: reports of a fast heart rate (tachycardia) in 3%, against 0.9% on placebo; heart rate rose by 4 to 5 beats a minute on average, against 0.5 on placebo.
- Low blood pressure: 2%, against 0.5% on placebo. Among people on Foundayo, it was reported by 4% of those also taking blood-pressure medicines, against 1% of those who were not.
Managing side effects: In the trials, nausea, vomiting and diarrhea were more common while the dose was being raised and decreased over time; 4% of people who had stomach side effects described them as severe. The slow build-up exists for this reason. Drink fluids, because dehydration from vomiting or diarrhea can harm the kidneys. Contact your provider right away if nausea, vomiting or diarrhea does not go away. Dose increases are not automatic: your prescriber decides whether and when to go up.
Foundayo Cost & Savings (2026)
Savings programs: Foundayo Savings Card: commercially insured patients may pay as little as $25 per month if their plan covers Foundayo. Self-pay through LillyDirect starts at $149 a month at the 0.8 mg starting dose (prescription required, terms apply). Medicare and Medicaid patients are not eligible for the commercial savings card.
Who Should Avoid It and Other Precautions
Do Not Take It If You Have
- Personal or family history of medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A known serious allergic reaction to orforglipron or any ingredient in Foundayo
Other Label Precautions
- Stop Foundayo when a pregnancy is recognized, because weight loss offers no benefit in pregnancy and may harm the baby.
- Foundayo is not recommended for people with severe gastroparesis (very slow stomach emptying).
- Foundayo is not recommended for people with severe liver impairment (Child-Pugh Class C).
- Foundayo is not recommended while breastfeeding.
- Taking Foundayo with another GLP-1 medicine is not recommended.
What to Expect, Month by Month
You start at 0.8 mg once a day, with or without food.
After at least 30 days on the 0.8 mg starting dose, the dose goes up to 2.5 mg.
After at least 30 days on 2.5 mg, the dose goes up to 5.5 mg. Your prescriber may then raise it to 9 mg, 14.5 mg and 17.2 mg, the highest dose, with at least 30 days on each step, depending on how well it works and how you feel.
In ATTAIN-1, adults without diabetes on 17.2 mg lost 12.4% of their body weight on average after 72 weeks, estimated assuming everyone stayed on treatment (11.1% counting everyone who started). Waist size, blood pressure, triglycerides and non-HDL cholesterol also improved compared with placebo.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. When you start Foundayo, your prescriber may lower your insulin or sulfonylurea dose.
Foundayo slows how fast your stomach empties, which can change how other medicines taken by mouth are absorbed. Tell your prescriber about every medicine you take.
Some medicines change how much Foundayo is in your blood by acting on an enzyme called CYP3A4. With a medicine that strongly blocks this enzyme, the label caps Foundayo at 9 mg a day, and it says to avoid strong blockers that also block a transporter called OATP1B, such as ritonavir. Medicines that strongly speed up this enzyme lower Foundayo levels and may make it work less well, so the label says to avoid them. With a medicine that moderately speeds it up, the label says your prescriber should check how well Foundayo is working and raise the dose if needed. Show your prescriber and pharmacist a list of every medicine you take.
Do not take more than 20 mg of simvastatin a day with Foundayo. In testing, Foundayo doubled the amount of the active form of simvastatin in the body.
The FDA label tells prescribers to advise anyone on birth control pills to switch to a non-oral method, or add a barrier method such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase. This is not optional advice in the label, and Foundayo may cause fetal harm. Methods that are not swallowed, such as the patch, ring, implant, injection or IUD, are not affected.
Special Situations
Do not use during pregnancy. The label says to stop Foundayo once a pregnancy is known and to use effective birth control while taking it. Tell your prescriber if you plan to become pregnant. Based on animal studies, there may be risks to the baby.
The label says Foundayo is not recommended while breastfeeding. Orforglipron passed into the milk of rats, and there are no data in people.
No dose change needed at any level, including end-stage kidney disease. Separately, and for everyone rather than kidney patients alone, the label warns that severe vomiting or diarrhea can dehydrate you enough to injure the kidneys, so stay well hydrated, especially during dose increases.
Foundayo is not recommended if you have severe liver impairment (Child-Pugh Class C). That is the wording the label itself uses, in its summary box, and it is not a data gap. No dose change is needed for mild or moderate.
In the trials, 13% of the people who took Foundayo were 65 or older, and the label reports no overall differences in safety or effectiveness between them and younger adults. In a later post hoc analysis of adults 65 and older without diabetes, Lilly reported 13.0% average weight loss in the observed data at the highest dose after 72 weeks, against 1.6% on placebo; post hoc analyses are exploratory. Severe vomiting or diarrhea can dehydrate anyone enough to harm the kidneys, so drink fluids and tell your prescriber if it does not stop.
Foundayo is approved for adults only. The label says its safety and effectiveness have not been established in children.
What Happens If You Stop
The sources we reviewed do not establish how much weight people regain after stopping Foundayo. In trials of the injections, a large share of the lost weight came back within a year of stopping: about two thirds for semaglutide 2.4 mg, the dose in Wegovy (STEP 1 extension), and about half for tirzepatide (SURMOUNT-4). Those are different drugs, and their results may not apply to Foundayo. In ATTAIN-MAINTAIN, published in May 2026, people who had been on Wegovy or Zepbound in an earlier trial switched to Foundayo or a placebo. Among those whose weight had levelled off, the published results estimated that people on Foundayo kept about 79% (from Wegovy) or 75% (from Zepbound) of the weight they had lost after a year, against about 38% and 49% on placebo. These model-based estimates include outcomes whether or not people kept taking the medicine. That trial tested switching to Foundayo, not stopping it.
How to make stopping easier: Talk with your prescriber before stopping or lowering your dose. The label pairs the medicine with a reduced-calorie diet and more physical activity.
Foundayo FAQs
Foundayo is a daily GLP-1 pill. Wegovy and Zepbound are weekly injections. Estimated assuming everyone stayed on treatment, average weight loss in their separate trials was about 12.4% for Foundayo, 16.9% for Wegovy and 22.5% for Zepbound. Foundayo has not been tested against either injection in a weight-loss trial, so these are not head-to-head results. It removes the needle, refrigeration, and weekly-shot routine entirely. For people who cannot tolerate injections, travel a lot, or want a simpler routine, a pill is a real alternative. Note that Foundayo is not the only one now: the Wegovy pill arrived in January 2026. Both start at $149 a month for self-pay at their lowest dose, though the Wegovy pill has to be taken on an empty stomach with a 30-minute wait, which Foundayo does not.
They are the two daily GLP-1 pills approved for weight loss, and they are not the same kind of drug. The Wegovy pill is oral semaglutide, a peptide, so it has to be taken on an empty stomach in the morning with no more than 4 ounces of water, and you wait 30 minutes before eating, drinking or taking anything else. Foundayo is a small molecule, so you take it whenever you like, with or without food. In their separate trials, counting everyone who started, average weight loss was 13.6% over 64 weeks for the Wegovy pill and 11.1% over 72 weeks for Foundayo, and both pills start at $149 a month for self-pay at their lowest dose. Foundayo has fewer rules about when to take it. Neither has been tested against the other in a single trial, so treat those percentages as coming from separate studies rather than a head-to-head.
Both are GLP-1 pills, but they are different kinds of molecule. Rybelsus is an oral version of injected semaglutide, a peptide, which means it has to be taken on an empty stomach with no food, drink, or other medications for at least 30 minutes after. Foundayo is a small-molecule drug: its label says to take it with or without food, and Lilly says it can be taken at any time of day. Rybelsus is approved for type 2 diabetes, not for weight loss.
Foundayo's list price, the wholesale price Lilly sets, is $649 a month. Bought directly through LillyDirect with a prescription, self-pay starts at $149 a month for the 0.8 mg starting dose, $149 for 2.5 mg and $199 for 5.5 mg (Lilly says those two prices are temporarily reduced through December 31, 2026), $299 for 9 mg, and $299 for 14.5 mg or 17.2 mg when you refill within 45 days. Taxes and fees may apply, and terms apply. If your commercial insurance covers Foundayo, the Lilly savings card can bring it as low as $25 a month; people on government programs such as Medicare and Medicaid cannot use the card. Eligible people with Medicare Part D may be able to get it for $50 a month through the Medicare GLP-1 Bridge (see the insurance answer below).
In the ATTAIN-1 trial, people on the highest dose, 17.2 mg, lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo. Those figures are estimated assuming everyone stayed on treatment. Counting everyone who started, the FDA label reports 11.1% at 17.2 mg, 8.3% at 9 mg and 7.4% at 5.5 mg. Results vary depending on dose, diet, exercise, and how your body responds.
It depends on your plan. Commercial plans set their own rules, so check whether yours covers Foundayo and needs prior authorization. Medicare: from July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge covers Foundayo for weight management for $50 a month for eligible people with Medicare Part D who are 18 or older. You need a qualifying BMI when you start treatment (35 or higher; 30 or higher with heart failure with preserved ejection fraction, high blood pressure that stays uncontrolled despite two medicines, or stage 3a or worse kidney disease; or 27 or higher with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease), an eligible Part D plan and an approved prior authorization; CMS says approval or denial is sent to the prescriber within 72 hours of submission. People with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced liver scarring (stage F2 to F3 fibrosis) are not eligible for the Bridge; their Part D plan may still cover a GLP-1. Medicaid: whether to cover drugs used for weight loss is each state's choice, so check your state's Medicaid preferred drug list.
Any licensed doctor or nurse practitioner can prescribe it. Use the directory below to find GLP-1 providers in your state, and ask whether they prescribe Foundayo.
Nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain are the most common. Nausea, vomiting and diarrhea were more common while the dose was being raised and became less common over time. Hair loss was reported by 4% to 5% of people on Foundayo vs 2% on placebo, more often by women. Severe vomiting or diarrhea can cause dehydration, so contact your provider right away if nausea, vomiting or diarrhea does not go away. Foundayo carries a boxed warning about thyroid C-cell tumors. Other GLP-1 drugs caused these tumors in rats and mice. Orforglipron did not, but it does not act in those animals, and whether these tumors matter for people is not known. Do not take Foundayo if you or a family member has had medullary thyroid cancer, or if you have MEN 2.
Looking for a Clinic?
Foundayo is a new medication. While our directory does not yet have confirmed Foundayo prescribers. Ask a GLP-1 clinic whether it prescribes Foundayo.
Browse GLP-1 Clinics →Related Foundayo resources
Looking for Foundayo?
Foundayo is a new medication. Our directory does not yet have confirmed Foundayo prescribers. Browse our 3,303 GLP-1 clinics and ask whether they prescribe it.
References
These are the main clinical sources for this page. Prices, coverage rules and some trial figures come from manufacturer and government sources that are not all listed here. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Foundayo (orforglipron) tablets: prescribing information
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) The 72-week trial behind the ~11-12.4% figures.
Drug facts on this page last checked against these sources August 2026; page last updated October 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. Clinical data comes from FDA prescribing information, published trials and, where the page says so, manufacturer trial announcements. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.